

# Downregulated miR-205-5p decreases cell proliferation, migration, and invasion of human cervical cancer cells

Rhafaella Lima Causin<sup>1</sup>, André van Helvoort Lengert<sup>1</sup>, Izabela Nathália Faria Gomes<sup>1</sup>, Ana Julia Aguiar de Freitas<sup>1</sup>, Marcela Nunes Rosa<sup>1</sup>, Laura Sichero<sup>2</sup>, Luisa Lina Villa<sup>2</sup>, Viviane Aline Oliveira Silva<sup>1</sup>, Rui Manuel Reis<sup>1</sup>, Ricardo Reis<sup>3</sup>, Marcia Maria Chiquitelli Marques<sup>1,4</sup>.

1 - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.

2- Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo FMUSP HC, São Paulo, Brazil.

3- Gynecologic Oncology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

4- Barretos School of Health Sciences, Dr. Paulo Prata – FACISB, Barretos, SP, Brazil.

## Background


Growing evidence supports that some epigenetic changes may contribute to the acquisition of hallmark capabilities during cervical tumor development and malignant progression. MicroRNAs (miRNAs) function to modulate the pathophysiologic mechanism in cervical cancer through the cancer signaling pathways regulation, which might offer a new approach for diagnosis and treatment cervical cancer patients in the future. Recent studies have shown that miR-205-5p could be used as good biomarkers for CIN 3 lesions. In addition, these miRNAs may be involved in crucial stages of cervical cancer progression.

## Aim

To evaluate *in vitro* the functional role of miR-205-5p in the process of proliferation, migration, and invasion of cervical cancer cell lines.

## Methods

### qRT-PCR



**Control cell:** HaCaT  
**Cell lines panel:** HeLa, SiHa, CasKi, C4-I, C33-A, HCB-514

• Housekeeping: U6

### TRANSFECTION



**miRNA inhibitor:** miRCURY LNA miRNA Inhibitors (20nM), named: anti-miR-130a-3p

**Transfection agent:** siPORT NeoFX (2.5µL)

### FUNCTIONAL ASSAY




**Proliferation:** Colony Formation Assay

**Migration:** Wound healing and transwell

**Invasion:** Transwell with Matrigel


## Results

✓ We identified that miR-205-5p were overexpressed in CaSki, C4-I, and HCB-514 cells:




**Figure 1.** miR-205-5p was highly expressed in the cervical cancer cells. CaSki, C-4I, and HCB-514 cell lines had significantly higher expression of miR-205-5p than the non-tumorigenic epithelial cell line HaCaT. The standard deviation bars were also included. ns: not significant; \*\*P < 0.0021; \*\*\*P < 0.0002; \*\*\*\*P < 0.0001.

✓ Transfection for miR-205-5p inhibition:




**Figure 2.** anti-miR-205-5p inhibition in the cervical cancer cells. The standard deviation bars were also included. \*\*\*\*P < 0.0001.

✓ Proliferation:




**Figure 3.** anti-miR-205-5p inhibited the proliferation of cervical cancer cells. A colony formation assay was used to test the proliferation of CaSki, and HCB-514 cells, which showed a smaller clone number in the anti-miR-205-5p group. The standard deviation bars were also included. \*\* P = 0.0021; \*\*\*\* P < 0.0001.

✓ Migration:




**Figure 4.** anti-miR-205-5p inhibited the migration of cervical cancer cells using wound healing assay. The standard deviation bars were also included. \*\* P = 0.0021; \*\*\*P < 0.0002; \*\*\*\* P < 0.0001.



**Figure 5.** anti-miR-205-5p inhibited the migration of cervical cancer cells using Transwell assay. The standard deviation bars were also included. \*\*\*\* P < 0.0001.

✓ Invasion:



**Figure 5.** anti-miR-205-5p inhibited the invasion of cervical cancer cells using Transwell assay with Matrigel. The standard deviation bars were also included. \*\*\*\*P = 0.0016; \*\*\*\* P < 0.0001.

## Conclusion

Our findings reveal novel functional roles of miR-205-5p in human cervical cancer cell lines, which may provide new insights into its role in the cervical cancer progression and its potential value for clinical diagnosis.

## Author's contact